Search Results: immunotherapy

• For Researchers

On your marks, get set… start-up!

Explore three of the latest companies to come out of one of our entrepreneurial programmes. Explore three of the latest companies to come out of one of our entrepreneurial programmes.

13 August 2021

• Health & Medicine

New option to treat advanced oesophageal cancer approved for NHS in Scotland

The Scottish Medicines Consortium (SMC) has approved the immunotherapy drug nivolumab (Opdivo) for some patients with advanced oesophageal cancer. The Scottish Medicines Consortium (SMC) has approved the immunotherapy drug nivolumab (Opdivo) for some patients with advanced oesophageal cancer.

11 August 2021

• Charity News

Charity ‘looks to the future with renewed optimism’

Cancer Research UK's Annual Report and Accounts 2020/21 reveals the impact of the pandemic on its income and spend on charitable activities over the past year. Cancer Research UK's Annual Report and Accounts 2020/21 reveals the impact of the pandemic on its income and spend on charitable activities over the past year.

21 July 2021

• Health & Medicine

Blood test could tailor treatment after surgery

A new study is looking at how blood tests after cancer surgery can be used to select patients for additional treatment, potentially sparing some patients from unnecessary, often toxic, treatment whilst ensuring those who need it get it as early as possible. A new study is looking at how blood tests after cancer surgery can be used to select patients for additional treatment, potentially sparing some patients from unnecessary, often toxic, treatment whilst ensuring those who need it get it as early as possible.

14 July 2021

• Science & Technology
• Health & Medicine

Scientists trial new way to boost CAR T-cell therapy

Cancer Research UK is collaborating with Aleta Biotherapeutics (Aleta) to trial a new therapy that ‘reboots’ a treatment for some people with blood cancer whose cancer starts to come back. Cancer Research UK is collaborating with Aleta Biotherapeutics (Aleta) to trial a new therapy that ‘reboots’ a treatment for some people with blood cancer whose cancer starts to come back.

23 June 2021

• Health & Medicine

Cancer Research UK spin-out gets US approval to trial unique T-cell therapy

Cancer Research UK’s spin-out, GammaDelta Therapeutics, has been given approval to trial its unique T-cell therapy in the US.   Cancer Research UK’s spin-out, GammaDelta Therapeutics, has been given approval to trial its unique T-cell therapy in the US.  

18 June 2021

• For Supporters
• Science & Technology

David Dangoor: “Education is a treasure that you give someone and they carry with them all their life”

The businessman, philanthropist and long-standing Cancer Research UK supporter tells us about his family’s latest £1.2m donation. The businessman, philanthropist and long-standing Cancer Research UK supporter tells us about his family’s latest £1.2m donation.

14 June 2021

• Science & Technology
• Health & Medicine

ASCO 2021 news: follow-up treatments pave the way

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented. One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.

9 June 2021

• Policy & Insight

Opinion: ‘The UK must be more ambitious than just clearing the cancer backlog’

Despite staff working flat out, the pandemic has been devastating for NHS cancer services, writes Cancer Research UK's chief clinician. Despite staff working flat out, the pandemic has been devastating for NHS cancer services, writes Cancer Research UK's chief clinician.

24 May 2021

• For Supporters

Partnership in a pandemic: how Credit Suisse delivered an incredible Charity of the Year partnership despite lockdown

We explore how our partner, Credit Suisse, adapted to significant changes in the fundraising environment to exceed its original targets for the partnership. We explore how our partner, Credit Suisse, adapted to significant changes in the fundraising environment to exceed its original targets for the partnership.

20 May 2021

• Health & Medicine

Cancer Research UK spin-out goes public, ready to invest more in precision T cell therapies

Cancer Research UK’s spinout, Achilles Therapeutics plc (‘Achilles’), has raised $175.5 million through the closing of its initial public offering (IPO). Cancer Research UK’s spinout, Achilles Therapeutics plc (‘Achilles’), has raised $175.5 million through the closing of its initial public offering (IPO).

18 May 2021

• For Researchers

Mitochondrial DNA in cancer: small genome, big impact

Payam Gammage believes understanding the mutations in mtDNA could reveal indicators of cancer prognosis and a new focus for therapeutics. Payam Gammage believes understanding the mutations in mtDNA could reveal indicators of cancer prognosis and a new focus for therapeutics.

5 May 2021